Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast

Cathie Wood’s Ark Invest increased its exposure to AI infrastructure, digital platforms, and biotechnology, led by purchases of $25.9M of CoreWeave (CRWV), $24.4M of Meta Platforms (META) and $17.6M of Recursion Pharmaceuticals (RXRX). The firm also bought $16.3M of Cerebras Systems (CBRS) and $9.4M of Rocket Lab (RKLB).

In biotechnology, Ark added to its positions in Freenome (FRNM), CRISPR Therapeutics (CRSP), Compass Pathways (CMPS), Beam Therapeutics (BEAM), Guardant Health (GH), Alamar Biosciences (ALMR), Kymera Therapeutics (KYMR), Intellia Therapeutics (NTLA), Nurix Therapeutics (NRIX), Scribe Therapeutics (SCTX) and Iambic Therapeutics (IAM).

On the selling side, healthcare accounted for Ark’s largest disclosed reductions. The firm sold 3.14M shares of Personalis (PSNL), worth $52.2M, and $16.1M of CareDx (CDNA), while cutting its position in 10x Genomics (TXG) by $8.3M. It also reduced its holdings in Twist Bioscience (TWST).

In software and technology, Ark sold $12.3M of Palantir Technologies (PLTR) and $12.2M of Shopify (SHOP), along with $7.7M of Amazon (AMZN). It also trimmed Teradyne (TER) and the ARK 21Shares Bitcoin ETF (ARKB), while adding to Symbotic (SYM) and Kodiak AI (KDK).

In consumer-facing businesses, Ark sold 797K shares of Toast (TOST), worth $24.3M, and reduced its DraftKings (DKNG) holdings by $4.8M. It also cut its positions in Alibaba Group (BABA) and Block (XYZ). Separately, Ark sold $10.1M of Everpure (P).